|
1
|
Li Z, Dou P, Liu T and He S: Application
of long noncoding RNAs in osteosarcoma: Biomarkers and therapeutic
targets. Cell Physiol Biochem. 42:1407–1419. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Isakoff MS, Bielack SS, Meltzer P and
Gorlick R: Osteosarcoma: Current treatment and a collaborative
pathway to success. J Clin Oncol. 33:3029–3035. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Ritter J and Bielack SS: Osteosarcoma. Ann
Oncol. 21 (Suppl 7):vii320–vii325. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Stiller CA, Bielack SS, Jundt G and
Steliarova-Foucher E: Bone tumours in European children and
adolescents, 1978–1997. Report from the automated childhood cancer
information system project. Eur J Cancer. 42:2124–2135. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Bartel DP: MicroRNAs: Genomics,
biogenesis, mechanism, and function. Cell. 116:281–297. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Kim VN and Nam JW: Genomics of microRNA.
Trends Genet. 22:165–173. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Pasquinelli AE, Hunter S and Bracht J:
MicroRNAs: A developing story. Curr Opin Genet Dev. 15:200–205.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
An JX, Ma MH, Zhang CD, Shao S, Zhou NM
and Dai DQ: miR-1236-3p inhibits invasion and metastasis in gastric
cancer by targeting MTA2. Cancer Cell Int. 18:662018. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Gao R, Cai C, Gan J, Yang X, Shuang Z, Liu
M, Li S and Tang H: miR-1236 down-regulates alpha-fetoprotein, thus
causing PTEN accumulation, which inhibits the PI3K/Akt pathway and
malignant phenotype in hepatoma cells. Oncotarget. 6:6014–6028.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Wang C, Tang K, Li Z, Chen Z, Xu H and Ye
Z: Targeted p21(WAF1/CIP1) activation by miR-1236 inhibits cell
proliferation and correlates with favorable survival in renal cell
carcinoma. Urol Oncol. 34:59.e23–e34. 2016. View Article : Google Scholar
|
|
11
|
Wang Y, Yan S, Liu X, Zhang W, Li Y, Dong
R, Zhang Q, Yang Q, Yuan C, Shen K and Kong B: miR-1236-3p
represses the cell migration and invasion abilities by targeting
ZEB1 in high-grade serous ovarian carcinoma. Oncol Rep.
31:1905–1910. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Poos K, Smida J, Nathrath M, Maugg D,
Baumhoer D and Korsching E: How microRNA and transcription factor
co-regulatory networks affect osteosarcoma cell proliferation. PLoS
Comput Biol. 9:e10032102013. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Jundt G: Updates to the WHO classification
of bone tumours. Pathologe. 39:107–116. 2018.(In German).
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Chen J, Liu G, Wu Y, Ma J, Wu H, Xie Z,
Chen S, Yang Y, Wang S, Shen P, et al: CircMYO10 promotes
osteosarcoma progression by regulating miR-370-3p/RUVBL1 axis to
enhance the transcriptional activity of β-catenin/LEF1 complex via
effects on chromatin remodeling. Mol Cancer. 18:1502019. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Martins-Neves SR, Paiva-Oliveira DI,
Fontes-Ribeiro C, Bovée JVMG, Cleton-Jansen A-M and Gomes CMF:
IWR-1, a tankyrase inhibitor, attenuates Wnt/β-catenin signaling in
cancer stem-like cells and inhibits in vivo the growth of a
subcutaneous human osteosarcoma xenograft. Cancer Lett. 414:1–15.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Mu Y, Zhang L, Chen X, Chen S, Shi Y and
Li J: Silencing microRNA-27a inhibits proliferation and invasion of
human osteosarcoma cells through the SFRP1-dependent Wnt/β-catenin
signaling pathway. Biosci Rep. 39:BSR201823662019. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Li X, Lu Q, Xie W, Wang Y and Wang G:
Anti-tumor effects of triptolide on angiogenesis and cell apoptosis
in osteosarcoma cells by inducing autophagy via repressing
Wnt/β-catenin signaling. Biochem Biophys Res Commun. 496:443–449.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Kaldis P and Pagano M: Wnt signaling in
mitosis. Dev Cell. 17:749–750. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Micalizzi DS, Farabaugh SM and Ford HL:
Epithelial-mesenchymal transition in cancer: Parallels between
normal development and tumor progression. J Mammary Gland Biol
Neoplasia. 15:117–134. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Whelan JS and Davis LE: Osteosarcoma,
chondrosarcoma, and chordoma. J Clin Oncol. 36:188–193. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Bian T, Jiang D, Liu J, Yuan X, Feng J, Li
Q, Zhang Q, Li X, Liu Y and Zhang J: miR-1236-3p suppresses the
migration and invasion by targeting KLF8 in lung adenocarcinoma
A549 cells. Biochem Biophys Res Commun. 492:461–467. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Zhao SJ, Jiang YQ, Xu NW, Zhang Q, Wang
SY, Li J, Wang YH, Zhang YL, Jiang SH, Wang YJ, et al: SPARCL1
suppresses osteosarcoma metastasis and recruits macrophages by
activation of canonical WNT/β-catenin signaling through
stabilization of the WNT-receptor complex. Oncogene. 37:1049–1061.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Matushansky I, Hernando E, Socci ND, Mills
JE, Matos TA, Edgar MA, Singer S, Maki RG and Cordon-Cardo C:
Derivation of sarcomas from mesenchymal stem cells via inactivation
of the Wnt pathway. J Clin Invest. 117:3248–3257. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Cai Y, Mohseny AB, Karperien M, Hogendoorn
PC, Zhou G and Cleton-Jansen AM: Inactive Wnt/beta-catenin pathway
in conventional high-grade osteosarcoma. J Pathol. 220:24–33. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Basu-Roy U, Seo E, Ramanathapuram L, Rapp
TB, Perry JA, Orkin SH, Mansukhani A and Basilico C: Sox2 maintains
self renewal of tumor-initiating cells in osteosarcomas. Oncogene.
31:2270–2282. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Pridgeon MG, Grohar PJ, Steensma MR and
Williams BO: Wnt signaling in ewing sarcoma, osteosarcoma, and
malignant peripheral nerve sheath tumors. Curr Osteoporos Rep.
15:239–246. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Li C, Shi X, Zhou G, Liu X, Wu S and Zhao
J: The canonical Wnt-beta-catenin pathway in development and
chemotherapy of osteosarcoma. Front Biosci (Landmark Ed).
18:1384–1391. 2013. View
Article : Google Scholar : PubMed/NCBI
|
|
29
|
Li Z, Li Y, Wang N, Yang L, Zhao W and
Zeng X: miR-130b targets NKD2 and regulates the Wnt signaling to
promote proliferation and inhibit apoptosis in osteosarcoma cells.
Biochem Biophys Res Commun. 471:479–485. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Zhao S, Kurenbekova L, Gao Y, Roos A,
Creighton CJ, Rao P, Hicks J, Man TK, Lau C, Brown AM, et al: NKD2,
a negative regulator of Wnt signaling, suppresses tumor growth and
metastasis in osteosarcoma. Oncogene. 34:5069–5079. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Yang G, Zhang C, Wang N and Chen J:
miR-425-5p decreases LncRNA MALAT1 and TUG1 expressions and
suppresses tumorigenesis in osteosarcoma via Wnt/β-catenin
signaling pathway. Int J Biochem Cell Biol. 111:42–51. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Xi Y and Chen Y: Wnt signaling pathway:
Implications for therapy in lung cancer and bone metastasis. Cancer
Lett. 353:8–16. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Nusse R and Clevers H: Wnt/β-catenin
signaling, disease, and emerging therapeutic modalities. Cell.
169:985–999. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Peng Z, Wu T, Li Y, Xu Z, Zhang S, Liu B,
Chen Q and Tian D: MicroRNA-370-3p inhibits human glioma cell
proliferation and induces cell cycle arrest by directly targeting
β-catenin. Brain Res. 1644:53–61. 2016. View Article : Google Scholar : PubMed/NCBI
|
